FDA Seeks To Resolve First Amendment Suit By Pacira
This article was originally published in The Gray Sheet
Executive Summary
Judge extends date for agency response to firm's complaint as parties continue settlement talks; case reveals two chinks in FDA’s off-label regulatory regime armor, former FDA advisor says.
You may also be interested in...
FDA Focusing Enforcement Efforts on GMP Compliance As Off-Label Prosecutions Wane
With recent court decisions largely stripping FDA of its powers to take pharmaceutical manufacturers to court for promoting off-label uses, the agency is shifting its enforcement focus to GMP violations, says attorney.
Pacira Drug Promotion Suit Settled With Broad Concessions From FDA
The agency will formally rescind Exparel warning letter and expand labeling to clarify that pain drug is not limited to any specific surgery. The drug case has been closely watched for implications on FDA's oversight of off-label communications for both drugs and devices.
Device Firms Should Not Ignore Pharma Off-Label Suits, Experts Say
While recent case law that appears to give industry more leverage in off-label communications involves drugs, the precedent should apply equally to devices, attorneys say. Nonetheless, companies should be cautious about moving full-steam ahead with off-label promotions